Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK).

Full DD Report for PRTK

You must become a subscriber to view this report.

Recent News from (NASDAQ: PRTK)

Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...
Source: SeekingAlpha
Date: May, 15 2018 10:33
Achaogen: Explicating The Prospects Of C-Scape
Long ago, Ben Graham taught me that ‘Price is what you pay; value is what you get.’ Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down. - Warren Buffett Achaogen (NASDAQ: AKAO ) is a stellar investment for opportun...
Source: SeekingAlpha
Date: May, 13 2018 06:36
Paratek Pharmaceuticals' (PRTK) CEO Michael Bigham on Q1 2018 Results - Earnings Call Transcript
Paratek Pharmaceuticals, Inc. (PRTK) Q1 2018 Earnings Conference Call May 9, 2018 08:30 AM ET Executives Michael Bigham - Chairman and CEO Doug Pagán - CFO Adam Woodrow - Chief Commercial Officer Evan Loh - President, COO and Chief Medical Officer Ben Strain - Executive ...
Source: SeekingAlpha
Date: May, 09 2018 12:10
Paratek up 1% on Q1 result
Paratek Pharmaceuticals ( PRTK ) Q1 results : Revenues: $10K (-44.4%); Operating Loss: ($26.7M) (+0.4%); Net Loss: ($27.8M) (-0.4%); Loss Per Share: ($0.91) (+20.2%); Quick Assets: $184.3M (+21.5%). More news on: Paratek Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and com...
Source: SeekingAlpha
Date: May, 09 2018 08:54
Paratek Pharmaceuticals EPS in-line
Paratek Pharmaceuticals (NASDAQ: PRTK ): Q1 EPS of -$0.91 in-line. More news on: Paratek Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 09 2018 07:33
Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results
-- New drug applications for omadacycline accepted for priority review by FDA; PDUFA action date in October 2018 -- -- Company on track for a first quarter 2019 omadacycline U.S. launch -- -- Company strengthens balance sheet to support commercial launch -- BOSTON, May 09, 2018...
Source: GlobeNewswire
Date: May, 09 2018 07:30
Iterum Therapeutics Plans $92 Million IPO
Quick Take Iterum Therapeutics ( ITRM ) intends to raise $92 million in an IPO from the sale of its common stock, according to an S-1 regulatory filing . The firm is a late clinical-stage biopharma developing treatments for urinary tract and intra-abdominal infections. ITRM is enhanci...
Source: SeekingAlpha
Date: May, 07 2018 12:02
Editor's Notes: Flipping The Script On Alibaba During Earnings Season
We’re flush in earnings season and that tends to shake out some opportunities one way or another. The best investors can anticipate when an earnings move is going to happen, right? Or maybe they wait and then act when the facts are in. Or they pay attention to the long-term, slotting in...
Source: SeekingAlpha
Date: May, 04 2018 09:45
Is Paratek Pharmaceuticals Oversold?
This article was co-authored by Stepan Lavrouk, an analyst with Almington Capital. Paratek Pharmaceuticals ( PRTK ) is a clinical-stage biopharmaceutical company specializing in the development of treatments based on tetracycline chemistry. The company has two drug candidates: omadacycline...
Source: SeekingAlpha
Date: May, 02 2018 22:41
Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BOSTON, May 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that on April 30, 2018, the Company granted stock opt...
Source: GlobeNewswire
Date: May, 01 2018 16:01


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PRTK.

About Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK)

Logo for Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK)

Not available


Contact Information



Current Share Structure

  • Market Cap: $358,451,899 - 05/11/2018
  • Issue and Outstanding: 31,443,149 - 02/28/2018


Recent Filings from (NASDAQ: PRTK)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 09 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 05 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 05 2018



Daily Technical Chart for (NASDAQ: PRTK)

Daily Technical Chart for (NASDAQ: PRTK)

Stay tuned for daily updates and more on (NASDAQ: PRTK)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PRTK)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PRTK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of PRTK and does not buy, sell, or trade any shares of PRTK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: